Research Article
No access
Published Online: 25 October 2010

Prostaglandin Subtype-Selective and Non-Selective IOP-Lowering Comparison in Monkeys

Publication: Journal of Ocular Pharmacology and Therapeutics
Volume 25, Issue Number 1

Abstract

The aim of this study was to determine whether the magnitude of the intraocular-pressure (IOP)-lowering response in monkeys to the nonselective prostaglandin (PG)F2a-isopropyl ester (ie) can be reproduced by combining other PG-subtype-selective compounds. IOP was lowered by approximately 25% after 4–5 days of topical administration with latanoprost (FP agonist, 1.5 μg, q.d.), bimatoprost (prostamide, whose metabolites have been shown to be FP agonists; 9 μg, q.d.), or travoprost (FP agonist, 1.2 μg, q.d) or the EP2 agonist, butaprost (25 μg, b.i.d.). The EP1 agonist, 17-phenyl trinor (PhT) PGE2 (b.i.d.), and EP3 agonist, sulprostone (b.i.d.), had no IOP-lowering effects. The addition of butaprost, sulprostone (10 μg), or 17PhTPGE2 (25 μg) to latanoprost did not lower IOP more than latanoprost alone. However, treatment with the combination of latanoprost, 17PhTPGE2, butaprost, and sulprostone produced a similar 50–55% reduction in IOP, as did PGF2α-ie (b.i.d.). In conclusion, latanoprost, travoprost, and bimatoprost produce similar IOP-lowering responses in normotensive monkeys and are most efficacious when administered q.d. pm, compared to b.i.d. The combination of the FP, EP1, EP2, and EP3 agonists used in this study was sufficient to lower IOP by the same magnitude as PGF2α-ie, suggesting that combining PG-subtype agonists may be a potent antiglaucoma strategy.

Get full access to this article

View all available purchase options and get full access to this article.

References

1.
Stjernschantz J.Selén G.Ocklind A. et al. Effects of latanoprost and related prostaglandin analoguesA. AlmWeinreb R.N.Uveoscleral Outflow. Biology and Clinical AspectsLondonMosby-Wolfe Medical Communications199857-72. 1. Stjernschantz, J., Selén, G., Ocklind, A., et al. Effects of latanoprost and related prostaglandin analogues. In: A. Alm, and Weinreb, R.N., eds., Uveoscleral Outflow. Biology and Clinical Aspects. London: Mosby-Wolfe Medical Communications, 1998:57–72.
2.
Sharif N.A.Kelly C.R.Crider J.Y. et al. Ocular hypotensive FP prostaglandin (PG) analogs: PG receptor subtype binding affinities and selectivities, and agonist potencies at FP and other PG receptors in cultured cellsJ. Ocul. Pharmacol. Ther.19501-5152003. 2. Sharif, N.A., Kelly, C.R., Crider, J.Y., et al. Ocular hypotensive FP prostaglandin (PG) analogs: PG receptor subtype binding affinities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells. J. Ocul. Pharmacol. Ther. 19:501–515, 2003.
3.
Stjernschantz J.W. From PGF2a-isopropyl ester to latanoprost: A review of the development of Xalatan. The Proctor LectureInvest. Ophthalmol. Vis. Sci.421134-11452001. 3. Stjernschantz, J.W. From PGF2a-isopropyl ester to latanoprost: A review of the development of Xalatan. The Proctor Lecture. Invest. Ophthalmol. Vis. Sci. 42:1134–1145, 2001.
4.
Bito L.Z. A new approach to the medical management of glaucoma, from the bench to the clinic, and beyond [Proctor lecture]Invest. Ophthalmol. Vis. Sci.421126-11332001. 4. Bito, L.Z. A new approach to the medical management of glaucoma, from the bench to the clinic, and beyond [Proctor lecture]. Invest. Ophthalmol. Vis. Sci. 42:1126–1133, 2001.
5.
Crawford K.Kaufman P.L.Gabelt B.T. Effects of topical PGF2a on aqueous humor dynamics in cynomolgus monkeysCurr. Eye Res.61035-10441987. 5. Crawford, K., Kaufman, P.L., and Gabelt, B.T. Effects of topical PGF2a on aqueous humor dynamics in cynomolgus monkeys. Curr. Eye Res. 6:1035–1044, 1987.
6.
Alexander C.L.Miller S.J.Abel S.R. Prostaglandin analog treatment of glaucoma and ocular hypertensionAnn. Pharmacother.36504-5112002. 6. Alexander, C.L., Miller, S.J., and Abel, S.R. Prostaglandin analog treatment of glaucoma and ocular hypertension. Ann. Pharmacother. 36:504–511, 2002.
7.
Eisenberg D.L.Toris C.B.Camras C.B. Bimatoprost and travoprost: A review of recent studies of two new glaucoma drugsSurv. Ophthalmol.47S105-S1152002. 7. Eisenberg, D.L., Toris, C.B., and Camras, C.B. Bimatoprost and travoprost: A review of recent studies of two new glaucoma drugs. Surv. Ophthalmol. 47:S105–S115, 2002.
8.
Coleman R.A.Kennedy I.Humphrey P.P.A. et al. Prostanoids and their ReceptorsSammes P.G.Taylor J.B.“Comprehensive Medicinal Chemistry: The Rational Design, Mechanistic Study, & Therapeutic Application of Chemical Compounds,”1stNew YorkPergamon Press1990643-714. 8. Coleman, R.A., Kennedy, I., Humphrey, P.P.A., et al. Prostanoids and their Receptors. In: Sammes, P.G., and Taylor, J.B., eds., “Comprehensive Medicinal Chemistry: The Rational Design, Mechanistic Study, & Therapeutic Application of Chemical Compounds,” 1st ed. New York: Pergamon Press, 1990:643–714.
9.
Sharif N.A.Crider J.Y.Husain S. et al. Human ciliary muscle cell responses to FP-class prostaglandin analogs: Phosphoinositide hydrolysis, intracellular Ca2+ mobilization, and MAP kinase activationJ. Ocul. Pharmacol. Ther.19437-4552003. 9. Sharif, N.A., Crider, J.Y., Husain, S., et al. Human ciliary muscle cell responses to FP-class prostaglandin analogs: Phosphoinositide hydrolysis, intracellular Ca2+ mobilization, and MAP kinase activation. J. Ocul. Pharmacol. Ther. 19:437–455, 2003.
10.
Bhattacherjee P.Shawn Williams B.Paterson C.A. Responses of intraocular pressure, the pupil of feline eyes to prostaglandin EP1, FP receptor agonistsInvest. Ophthalmol. Vis. Sci.403047-30531999. 10. Bhattacherjee, P., Shawn Williams, B., and Paterson, C.A., Responses of intraocular pressure and the pupil of feline eyes to prostaglandin EP1 and FP receptor agonists. Invest. Ophthalmol. Vis. Sci. 40:3047–3053, 1999.
11.
Lawrence R.A.Jones R.L.Wilson N.H. Characterization of receptors involved in the direct and indirect actions of prostaglandins E and I on the guinea-pig ileumBr. J. Pharmacol.105271-2781992. 11. Lawrence, R.A., Jones, R.L., and Wilson, N.H. Characterization of receptors involved in the direct and indirect actions of prostaglandins E and I on the guinea-pig ileum. Br. J. Pharmacol. 105:271–278, 1992.
12.
Bhattacherjee P.Mukhopadhyay P.Tilley S.L. et al. Bloodaqueous barrier in prostaglandin EP2 receptor knockout miceOcul. Immunol. Inflamm.1087-1962002. 12. Bhattacherjee, P., Mukhopadhyay, P., Tilley, S.L., et al. Bloodaqueous barrier in prostaglandin EP2 receptor knockout mice. Ocul. Immunol. Inflamm. 10:87–196, 2002.
13.
Coleman R.A.Kennedy I.Sheldrick R.L. New evidence with selective agonists and antagonists for the subclassification of PGE2-sensitive (EP) receptorsAdv. PG. Tx. Lt. Res.17A467-4701987. 13. Coleman, R.A., Kennedy, I., and Sheldrick, R.L. New evidence with selective agonists and antagonists for the subclassification of PGE2-sensitive (EP) receptors. Adv. PG. Tx. Lt. Res. 17A:467–470, 1987.
14.
Abramovitz M.Adam M.Boie Y. et al. The utilization of recombinant prostanoid receptors to determine the affinities annd selectivities of prostaglandins and related analogsBiochim. Biophys. Acta.1483285-2932000. 14. Abramovitz, M., Adam, M., Boie, Y., et al. The utilization of recombinant prostanoid receptors to determine the affinities annd selectivities of prostaglandins and related analogs. Biochim. Biophys. Acta. 1483:285–293, 2000.
15.
Croft M.A.Kiland J.Gange S.J. et al. Comparison of Goldmann tonometry measurements using creamer vs fluorescein in cynomolgus monkeysLakshminarayanan V.“Basic and Clinical Applications of Vision Science. The Professore Jay M. Enoch Festschrift Volume, Documenta Ophthalmologica Proceedings Series, Vol 60.”DorderechtKluwer213-2161997. 15. Croft, M.A., Kiland, J., Gange, S.J., et al. Comparison of Goldmann tonometry measurements using creamer vs fluorescein in cynomolgus monkeys. In: Lakshminarayanan, V., ed., “Basic and Clinical Applications of Vision Science. The Professore Jay M. Enoch Festschrift Volume, Documenta Ophthalmologica Proceedings Series, Vol 60.” Dorderecht: Kluwer, 213–216, 1997.
16.
Kaufman P.L.Davis G.E. “Minified” Goldmann applanating prism for tonometry in monkeys and humansArch. Ophthalmol.98542-5461980. 16. Kaufman, P.L., and Davis, G.E. “Minified” Goldmann applanating prism for tonometry in monkeys and humans. Arch. Ophthalmol. 98:542–546, 1980.
17.
Gabelt B.T.Kaufman P.L. Bimatoprost for glaucoma therapy: Pharmacology, clinical efficacy, and controversyExp. Rev. Ophthalmol.1141-1582006. 17. Gabelt, B.T., and Kaufman, P.L. Bimatoprost for glaucoma therapy: Pharmacology, clinical efficacy, and controversy. Exp. Rev. Ophthalmol. 1:141–158, 2006.
18.
Gandolfi S.A.Cimino L. Effect of bimatoprost on patients with primary open-angle glaucoma or ocular hypertension who are nonresponders to latanoprostOphthalmology110609-6142003. 18. Gandolfi, S.A., and Cimino, L. Effect of bimatoprost on patients with primary open-angle glaucoma or ocular hypertension who are nonresponders to latanoprost. Ophthalmology. 110:609–614, 2003.
19.
Sonty S.Donthamsetti V.Vangipuram G. et al. Long-term IOP lowering with bimatoprost in open-angle glaucoma patients poorly responsive to latanoprostJ. Ocul. Pharmacol. Ther.24517-5202008. 19. Sonty, S., Donthamsetti, V., Vangipuram, G., et al. Long-term IOP lowering with bimatoprost in open-angle glaucoma patients poorly responsive to latanoprost. J. Ocul. Pharmacol. Ther. 24:517–520, 2008.
20.
Biswas S.Bhattacherjee P.Paterson C.A. Prostaglandin E2 receptor subtypes, EP1, EP2, EP3 and EP4, in human and mouse ocular tissues—a comparative immunohisto-chemical studyProstagl. Leukot. Essent. Fatty. Acids71277-2882004. 20. Biswas, S., Bhattacherjee, P., and Paterson, C.A. Prostaglandin E2 receptor subtypes, EP1, EP2, EP3 and EP4, in human and mouse ocular tissues—a comparative immunohisto-chemical study. Prostagl. Leukot. Essent. Fatty. Acids 71:277–288, 2004.
21.
Schlotzer-Schrebardt U.Zenkel M.Nusing R.M. Expression and localization of FP and EP prostanoid receptor subtypes in human ocular tissuesInvest. Ophthalmol. Vis. Sci.431475-14872002. 21. Schlotzer-Schrebardt, U., Zenkel, M., and Nusing, R.M. Expression and localization of FP and EP prostanoid receptor subtypes in human ocular tissues. Invest. Ophthalmol. Vis. Sci. 43:1475–1487, 2002.
22.
Mukhopadhyay P.Bian L.Yin H. et al. Localization of EP(1) and FP receptors in human ocular tissues by in situ hybridizationInvest. Ophthalmol. Vis. Sci.42424-4282001. 22. Mukhopadhyay, P., Bian, L., Yin, H., et al. Localization of EP(1) and FP receptors in human ocular tissues by in situ hybridization. Invest. Ophthalmol. Vis. Sci. 42:424–428, 2001.
23.
Nilsson S.F.Drecoll E.Lutjen-Drecoll E. et al. The prostanoid EP2 receptor agonist butaprost increases uveoscleral outflow in the cynomolgus monkeyInvest. Ophthalmol. Vis. Sci.474042-40492006. 23. Nilsson, S.F., Drecoll, E., Lutjen-Drecoll, E., et al. The prostanoid EP2 receptor agonist butaprost increases uveoscleral outflow in the cynomolgus monkey. Invest. Ophthalmol. Vis. Sci. 47:4042–4049, 2006.
24.
Woodward D.F.Lawrence R.A.Fairbairn C.E. et al. Intraocular pressure effects of selective prostanoid receptor agonists involve different receptor subtypes according to radioligand-binding studiesJ. Lipid. Metab.6545-5531993. 24. Woodward, D.F., Lawrence, R.A., Fairbairn, C.E., et al. Intraocular pressure effects of selective prostanoid receptor agonists involve different receptor subtypes according to radioligand-binding studies. J. Lipid. Metab. 6:545–553, 1993.
25.
Ota T.Aihara M.Saeki T. et al. The IOP-lowering effects and mechanism of action of tafluprost in prostanoid receptor-deficient miceBr. J. Ophthalmol.91673-6762007. 25. Ota, T., Aihara, M., Saeki, T., et al. The IOP-lowering effects and mechanism of action of tafluprost in prostanoid receptor-deficient mice. Br. J. Ophthalmol. 91:673–676, 2007.
26.
Ota T.Aihara M.Saeki T. et al. The effects of prostaglandin analoques on prostaoid EP1, EP2, and EP3 receptor-deficient miceInvest. Ophthalmol. Vis. Sci.473395-33992006. 26. Ota, T., Aihara, M., Saeki, T., et al. The effects of prostaglandin analoques on prostaoid EP1, EP2, and EP3 receptor-deficient mice. Invest. Ophthalmol. Vis. Sci. 47:3395–3399, 2006.
27.
Kharlamb A.B.Krauss A.H.Chen J. et al. Prostanoid EP4 receptor stimulation produces profound ocular hypotension that involves pressure dependent outflowInvest. Ophthalmol. Vis. Sci.45SupplAbs nr 10352004. 27. Kharlamb, A.B., Krauss, A.H., Chen, J., et al. Prostanoid EP4 receptor stimulation produces profound ocular hypotension that involves pressure dependent outflow. Invest. Ophthalmol. Vis. Sci. 45(Suppl):Abs nr 1035, 2004.
28.
Kharlamb A.B.Woodward D.F.Burk R.M. et al. Ciliary muscle relaxation does not explain the profound ocular hypotension produced by a selective prostanoid EP4 receptor agonist 3,7-dithia PGE1 in monkeysInvest. Ophthalmol. Vis. Sci.ARVO supplement:Abs nr 4132006. 28. Kharlamb, A.B., Woodward, D.F., Burk, R.M., et al. Ciliary muscle relaxation does not explain the profound ocular hypotension produced by a selective prostanoid EP4 receptor agonist 3,7-dithia PGE1 in monkeys. Invest. Ophthalmol. Vis. Sci. ARVO supplement:Abs nr 413, 2006.
29.
Gabelt B.T.Kaufman P.L. Prostaglandin F2a increases uveoscleral outflow in the cynomolgus monkeyExp. Eye Res.49389-4021989. 29. Gabelt, B.T., and Kaufman, P.L. Prostaglandin F2a increases uveoscleral outflow in the cynomolgus monkey. Exp. Eye Res. 49:389–402, 1989.
30.
Nilsson S.F.E.Samuelsson M.Bill A. et al. Increased uveoscleral outflow as a possible mechanism of ocular hypotension caused by prostaglandin F2a-1-isopropylester in the cynomolgus monkeyExp. Eye. Res.48707-7161989. 30. Nilsson, S.F.E., Samuelsson, M., Bill, A., et al. Increased uveoscleral outflow as a possible mechanism of ocular hypotension caused by prostaglandin F2a-1-isopropylester in the cynomolgus monkey. Exp. Eye. Res. 48:707–716, 1989.
31.
Gabelt B.T.Kaufman P.L. The effect of prostaglandin F2a on trabecular outflow facility in cynomolgus monkeysExp. Eye. Res.5187-911990. 31. Gabelt, B.T., and Kaufman, P.L. The effect of prostaglandin F2a on trabecular outflow facility in cynomolgus monkeys. Exp. Eye. Res. 51:87–91, 1990.
32.
Richter M.Krauss A.H-P.Woodward D.F. et al. Morphological changes in the anterior eye segment after long-term treatment with different receptor selective prostaglandin agonists and a prostamideInvest. Ophthalmol. Vis. Sci.444419-44262003. 32. Richter, M., Krauss, A.H-P., Woodward, D.F., et al. Morphological changes in the anterior eye segment after long-term treatment with different receptor selective prostaglandin agonists and a prostamide. Invest. Ophthalmol. Vis. Sci. 44:4419–4426, 2003.
33.
Weinreb R.N.Lindsey J.D.Marchenko G. et al. Prostaglandin FP agonists alter metalloproteinase gene expression in scleraInvest. Ophthalmol. Vis. Sci.454368-43772004. 33. Weinreb, R.N., Lindsey, J.D., Marchenko, G., et al. Prostaglandin FP agonists alter metalloproteinase gene expression in sclera. Invest. Ophthalmol. Vis. Sci. 45:4368–4377, 2004.
34.
Kim J-W.Lindsey J.D.Wang N. et al. Increased human scleral permeability with prostaglandin exposureInvest. Ophthalmol. Vis. Sci.421514-15212001. 34. Kim, J-W., Lindsey, J.D., Wang, N., et al. Increased human scleral permeability with prostaglandin exposure. Invest. Ophthalmol. Vis. Sci. 42:1514–1521, 2001.

Information & Authors

Information

Published In

cover image Journal of Ocular Pharmacology and Therapeutics
Journal of Ocular Pharmacology and Therapeutics
Volume 25Issue Number 1February 2009
Pages: 1 - 8
PubMed: 19232013

History

Published online: 25 October 2010
Published ahead of print: 22 February 2009
Published in print: February 2009
Accepted: 30 October 2008
Received: 16 August 2008

Permissions

Request permissions for this article.

Topics

Authors

Affiliations

B'Ann True Gabelt
Department of Ophthalmology and Visual Sciences, University of Wisconsin, Madison, Wisconsin.
Elizabeth A. Hennes
Department of Ophthalmology and Visual Sciences, University of Wisconsin, Madison, Wisconsin.
Mark A. Bendel
Department of Ophthalmology and Visual Sciences, University of Wisconsin, Madison, Wisconsin.
Chase E. Constant
Department of Ophthalmology and Visual Sciences, University of Wisconsin, Madison, Wisconsin.
Mehmet Okka
Department of Ophthalmology and Visual Sciences, University of Wisconsin, Madison, Wisconsin.
Current address: Department Ophthalmology, Selcuk University Medical School, Konya, Turkey.
Paul L. Kaufman
Department of Ophthalmology and Visual Sciences, University of Wisconsin, Madison, Wisconsin.

Notes

Reprint Requests: Paul L. KaufmanDepartment of Ophthalmology and Visual SciencesUniversity of Wisconsin3310 University Ave, Suite 206Madison, WI 53705-2135E-mail: [email protected]

Metrics & Citations

Metrics

Citations

Export citation

Select the format you want to export the citations of this publication.

View Options

Get Access

Access content

To read the fulltext, please use one of the options below to sign in or purchase access.

Society Access

If you are a member of a society that has access to this content please log in via your society website and then return to this publication.

Restore your content access

Enter your email address to restore your content access:

Note: This functionality works only for purchases done as a guest. If you already have an account, log in to access the content to which you are entitled.

View options

PDF/EPUB

View PDF/ePub

Full Text

View Full Text

Media

Figures

Other

Tables

Share

Share

Copy the content Link

Share on social media

Back to Top